/

Empresas

Eg

No verificado

Egle Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa

02/12/2025

Salud

Ciencia

Medicina - Varios

Farmacéutica

Biotecnología

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

Fuente

Egle Therapeutics

Editor

1.00

0

22/04/2025

Ferias y Congresos

Industria

Oncología

Salud

Biotecnología

Sanidad

Medicina - Varios

Farmacéutica

Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting

Fuente

Egle Therapeutics

Editor

1.00

0

17/03/2025

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Fuente

Egle Therapeutics

Editor

1.00

0

13/01/2025

Mercado laboral

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

Fuente

Egle Therapeutics

Editor

1.00

0

25/10/2024

Eventos

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting

Fuente

Egle Therapeutics

Editor

1.00

0

12/09/2024

Mercado laboral

Biotecnología

Sanidad

Salud

Oncología

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

Fuente

Egle Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0